PGF and non-small cell lung carcinoma: However, when the PLGF biomarker hypothesis for motesanib emerged, the large international, double-blind, randomized, placebo-controlled MONET1 study of motesanib plus carboplatin/paclitaxel in patients with NSCLC was already actively enrolling [27].